Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.

ABSTRACT:

Background

Tedizolid is a novel oxazolidinone antibacterial with potent activity against a wide range of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Although tedizolid is approved by the US Food and Drug Administration (FDA) for treatment of patients with acute bacterial skin and skin structure infection, commercial susceptibility testing products for tedizolid are not currently available. This study evaluated the usefulness of applying linezolid susceptibility test results as a surrogate for predicting susceptibility to tedizolid in clinically significant Gram-positive pathogens.

Methods

Gram-positive isolates (N = 10,702) were obtained from annual surveillance programs conducted between 2009 and 2012,

SUBMITTER: Zurenko G 

PROVIDER: S-EPMC4291835 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature